T-5224 Induces Ferroptosis in Multiple Myeloma
2026-08-27
The reference study links T-5224-mediated AP-1 inhibition to ferroptotic death of multiple myeloma cells through suppression of the PI3K/AKT pathway, reduced GPX4 and SLC7A11, and increased oxidative stress. Its rescue experiments with ferrostatin-1 and 740Y-P provide a mechanistic framework for studying AP-1 inhibition alongside bortezomib, while also highlighting the need for further validation beyond pharmacological evidence.
L. gasseri, NR1I3, and E-Cadherin in Colitis
2026-08-26
Qian et al. show that Lactobacillus gasseri ATCC33323 reduces DSS-induced colitis in mice and identify an intestinal E-cadherin-centered mechanism involving NR1I3-dependent CDH1 regulation. The study is notable for combining probiotic treatment, barrier phenotyping, intestinal E-cadherin semiknockdown, transcriptional analysis, and in vitro validation to move beyond an association between microbiota and inflammation.
SGI-1027 DNA Methyltransferase Inhibitor Workflows
2026-08-26
SGI-1027 combines cofactor-site DNMT inhibition with reported DNMT1 degradation, making it useful for connecting DNA methylation inhibition to gene expression and cancer-cell phenotypes. A gastric cancer study provides a practical framework for pairing RB1/DNMT1 measurements with proliferation, migration, invasion, and tumor-growth assays.
Lamotrigine: From Ion Channels to Translation
2026-08-25
A translational strategy for studying Lamotrigine across neuronal sodium channels, serotonin signaling, cardiac excitability, and CYP19-related endocrine biology while maintaining rigorous assay controls and evidence boundaries.
Wnt-O-GlcNAcylation Rewires Glycolysis in Bone
2026-08-25
The reference study identifies O-GlcNAcylation as a metabolic and post-translational mechanism that enables Wnt3a-driven osteoblastogenesis. Its central finding is that Wnt stabilizes PDK1 through modification at Ser174, thereby increasing aerobic glycolysis and supporting bone formation and fracture healing.
Cabozantinib in RCC: From Target Inhibition to Adaptation
2026-08-24
Cabozantinib and XL184 are best understood not only as potent multi-kinase inhibitors, but also as tools for studying how renal cell carcinoma rewires signaling under sustained therapeutic pressure. This thought-leadership article connects receptor pharmacology, phosphoproteomic adaptation, motility biology, assay design, and translational decision-making.
FH1 Small Molecule for iPS Hepatocyte Maturation
2026-08-23
FH1 small molecule helps researchers move beyond hepatocyte identity markers by improving albumin secretion, CYP3A4 levels, colony morphology, and AFP profiles in iPS-derived hepatocyte-like cells. This guide translates those findings into a controlled culture workflow, assay strategy, troubleshooting plan, and a cautious bridge to regulated gene-expression research.
Tolazoline for α2-Adrenergic Receptor Studies
2026-08-22
Tolazoline supports concentration-resolved studies of α2-adrenergic receptor signaling, airway smooth muscle responses, and pancreatic islet activity. Its useful differentiation is a dual pharmacology: receptor antagonism at lower experimental concentrations and ATP-sensitive potassium channel effects that become increasingly important at higher concentrations.
Z-VDVAD-FMK in Apoptosis Pathway Mapping
2026-08-21
Z-VDVAD-FMK enables mechanistic separation of caspase-2-associated apoptosis from caspase-1-driven pyroptosis. This article shows how to use the inhibitor in apoptosis assays inspired by new HOXC8–CASP1 findings in lung cancer research.
T-5224: C-Fos/AP-1 Inhibitor Evidence
2026-08-21
T-5224 is a selective C-Fos/AP-1 inhibitor for studying inflammatory transcription, matrix metalloproteinases, cytokines, and osteoclastogenic signaling. Product-dossier evidence supports activity in arthritis-related cellular and mouse models, while a 2024 study links T-5224-induced multiple myeloma cell death to PI3K/AKT-associated ferroptosis.
T-5224 Induces Ferroptosis in Multiple Myeloma
2026-08-20
The 2024 Heliyon study shows that T-5224 kills multiple myeloma cells through ferroptosis linked to suppression of PI3K/AKT signaling, rather than apoptosis alone. Pharmacological rescue experiments and combination testing with bortezomib provide a mechanistic framework for evaluating AP-1 inhibition as a strategy in myeloma research.
Pazopanib (GW-786034) in ATRX-Defined Glioma Models
2026-08-20
Pazopanib (GW-786034) enables pathway-level studies of VEGF signaling, PDGFR activity, angiogenesis inhibition, and tumor cell survival in cancer research. This workflow emphasizes ATRX-stratified glioma assays, controlled DMSO handling, orthogonal readouts, and cautious interpretation of combinations with temozolomide.
Ertugliflozin and Brain Insulin Signaling in Alzheimer’s
2026-08-19
This study tested whether the SGLT2 inhibitor ertugliflozin could reduce Alzheimer-like changes caused by intracerebroventricular streptozotocin, with particular attention to brain insulin signaling and tau hyperphosphorylation. In a rat model, treatment was associated with better cognitive performance, reduced hippocampal tau phosphorylation, and improvements in cholinergic, mitochondrial, apoptotic, and synaptic measures, while the findings remain preclinical and mechanistically associative.
Tolazoline for α2-Adrenergic Receptor Studies
2026-08-19
Tolazoline supports mechanism-focused studies of α2-adrenergic signaling, airway tone, and pancreatic islet function. This guide connects affinity measurements with functional assays while highlighting concentration-dependent channel effects, controls, and troubleshooting decisions.
N4-Acetylcytidine: RNA Assay Workflows
2026-08-18
Use N4-Acetylcytidine as a defined free ac4C nucleoside substrate, analytical reference, or control—not as a guaranteed source of RNA-incorporated modification. This guide translates recent ASCH-domain structural findings into practical enzyme assays, RNA comparisons, sample-preparation controls, and troubleshooting decisions.
457 records 7/31 page Previous Next First page 上5页 678910 下5页 Last page